A
Arena Pharmaceuticals
Arena is now part of Pfizer
About Arena Pharmaceuticals
Arena Pharmaceuticals was founded in 1997, establishing itself as a clinical-stage biopharmaceutical company based in San Diego, California. The company focused on discovering and developing novel drugs targeting G protein-coupled receptors, which play a crucial role in various physiological processes.
Over the years, Arena Pharmaceuticals made significant strides in the biotech industry, advancing its pipeline of drug candidates aimed at treating cardiovascular, autoimmune, and other diseases. The company's innovative approach and dedication to addressing unmet medical needs positioned it as a notable player in the pharmaceutical landscape.
Arena Pharmaceuticals' journey reached a pivotal moment in December 2021 when Pfizer, a global pharmaceutical giant, announced its intention to acquire the company. The acquisition was completed in March 2022, with Pfizer purchasing Arena Pharmaceuticals for approximately $6.7 billion in cash. This acquisition was driven by Pfizer's interest in Arena's promising treatment candidates, particularly those targeting diseases affecting the stomach and intestines.
The acquisition marked a significant milestone in Arena Pharmaceuticals' history, highlighting its success in developing potential therapies and attracting the attention of a major industry player like Pfizer. Today, Arena Pharmaceuticals' legacy continues under Pfizer's umbrella, contributing to the advancement of innovative treatments in the pharmaceutical industry.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1977
- Headquarters
- San Diego, United States
- Listing
- IPO 2021
- Employees
- 110
- Open positions
- None listed
- Dealroom signal
- 60.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology
- Business model
- Manufacturing
- Client focus
- b2c
- Investment activity
- 2 companies, latest Jul 2021
- Capital deployed
- $119M
- Preferred round
- SERIES B
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Dec 2021 | $6.7B | $6.7B | Pfizer | ↗ |
| POST IPO EQUITY✓Other financing | Apr 2017 | $79M | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Arena Pharmaceuticals is 13K monthly website visits, down 13.3% over the last three months. Arena Pharmaceuticals's team declined 26.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Aristea TherapeuticsSan Diego, United StatesA clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases
$252Mvaluation
Longboard PharmaceuticalsSan Diego, United StatesA clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases
$2.1Bvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors1 additional known investor
Pfizer
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Arena Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Arena Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.